- Home
- TBPH vs IAUX Comparison
TBPH vs IAUX Comparison
Compare TBPH & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- IAUX
- Stock Information
- Founded
- TBPH 2013
- IAUX 2020
- Country
- TBPH United States
- IAUX United States
- Employees
- TBPH N/A
- IAUX N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- IAUX
- Sector
- TBPH Health Care
- IAUX
- Exchange
- TBPH Nasdaq
- IAUX Nasdaq
- Market Cap
- TBPH 699.0M
- IAUX 775.8M
- IPO Year
- TBPH N/A
- IAUX N/A
- Fundamental
- Price
- TBPH $14.58
- IAUX $0.99
- Analyst Decision
- TBPH Strong Buy
- IAUX Buy
- Analyst Count
- TBPH 4
- IAUX 1
- Target Price
- TBPH $23.00
- IAUX $1.50
- AVG Volume (30 Days)
- TBPH 367.5K
- IAUX 7.0M
- Earning Date
- TBPH 11-11-2025
- IAUX 11-11-2025
- Dividend Yield
- TBPH N/A
- IAUX N/A
- EPS Growth
- TBPH N/A
- IAUX N/A
- EPS
- TBPH 0.26
- IAUX N/A
- Revenue
- TBPH $77,205,000.00
- IAUX $76,622,000.00
- Revenue This Year
- TBPH $79.82
- IAUX $79.79
- Revenue Next Year
- TBPH N/A
- IAUX $92.04
- P/E Ratio
- TBPH $56.32
- IAUX N/A
- Revenue Growth
- TBPH 24.49
- IAUX 40.21
- 52 Week Low
- TBPH $7.88
- IAUX $0.34
- 52 Week High
- TBPH $15.15
- IAUX $1.25
- Technical
- Relative Strength Index (RSI)
- TBPH 60.51
- IAUX 66.21
- Support Level
- TBPH $14.00
- IAUX $0.91
- Resistance Level
- TBPH $14.87
- IAUX $1.00
- Average True Range (ATR)
- TBPH 0.50
- IAUX 0.06
- MACD
- TBPH -0.02
- IAUX -0.01
- Stochastic Oscillator
- TBPH 62.00
- IAUX 66.27
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.